Literature DB >> 17989265

The challenges of managing cancer related venous thromboembolism in the palliative care setting.

S Noble1.   

Abstract

Cancer patients with venous thromboembolism (VTE) pose particular management challenges since they have an increased risk of bleeding and recurrent thrombosis compared to the non-cancer population. Also, as the disease progresses so do the hazards of anticoagulation, and patients in the palliative stages of their cancer could be viewed as a separate disease group with respect to diagnosis and management. As the focus from curative treatment moves towards symptom control, physicians face several challenges in providing the most appropriate care. Palliative care patients have rarely been included in research on VTE and the supporting evidence needs to be extrapolated cautiously. Quality of life aspects of VTE and their management may be a more appropriate outcome measure in this stage of disease than radiological end points. This paper looks at the challenges facing professionals in the management of VTE in the advanced cancer patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989265      PMCID: PMC2659959          DOI: 10.1136/pgmj.2007.061622

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  30 in total

1.  Role of D-dimers in diagnosis of venous thromboembolism.

Authors:  J Kelly; B J Hunt
Journal:  Lancet       Date:  2002-02-09       Impact factor: 79.321

2.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

3.  Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey.

Authors:  C C Kirwan; E Nath; G J Byrne; C N McCollum
Journal:  BMJ       Date:  2003-09-13

4.  Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial.

Authors:  A G Turpie
Journal:  Am J Cardiol       Date:  2000-12-28       Impact factor: 2.778

5.  Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study.

Authors:  N A Christakis; E B Lamont
Journal:  BMJ       Date:  2000-02-19

Review 6.  Plasma D-dimers in the diagnosis of venous thromboembolism.

Authors:  James Kelly; Anthony Rudd; Roger R Lewis; Beverley J Hunt
Journal:  Arch Intern Med       Date:  2002-04-08

7.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

8.  Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE.

Authors:  Robert A Wolff
Journal:  Cancer Treat Rev       Date:  2003-06       Impact factor: 12.111

9.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

Authors:  Guy Meyer; Zora Marjanovic; Judith Valcke; Bernard Lorcerie; Yves Gruel; Philippe Solal-Celigny; Christine Le Maignan; Jean Marc Extra; Paul Cottu; Dominique Farge
Journal:  Arch Intern Med       Date:  2002 Aug 12-26

10.  The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.

Authors:  S I R Noble; K Hood; I G Finlay
Journal:  Palliat Med       Date:  2007-09       Impact factor: 4.762

View more
  19 in total

1.  Predictors of anticoagulation in hospice patients with lung cancer.

Authors:  Holly M Holmes; Kevin T Bain; Ali Zalpour; Ruili Luo; Eduardo Bruera; James S Goodwin
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

Review 2.  Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review.

Authors:  Hanno Riess; Piet Habbel; Anja Jühling; Marianne Sinn; Uwe Pelzer
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

Review 3.  Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?

Authors:  A Maraveyas; M Johnson
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

4.  Idiopathic and recurrent thromboembolic phenomena in cancer patients.

Authors:  Miriam López-Gómez; César Gómez-Raposo; María Sereno Moyano; Enrique Casado-Sáenz; Jaime Feliú Batlle; Carolina Ortega Ruipérez; Manuel González Barón
Journal:  Clin Transl Oncol       Date:  2008-10       Impact factor: 3.405

Review 5.  Decision making about change of medication for comorbid disease at the end of life: an integrative review.

Authors:  Ronald T C M van Nordennen; Jan C M Lavrijsen; Kris C P Vissers; Raymond T C M Koopmans
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

6.  Venous thromboembolism and palliative care.

Authors:  Simon Noble
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

7.  Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS).

Authors:  Carme Font; Annmarie Nelson; Tanya Garcia-Fernandez; Hayley Prout; Peter Gee; Simon Noble
Journal:  Support Care Cancer       Date:  2018-04-07       Impact factor: 3.603

8.  Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.

Authors:  Simon Noble; Axel Matzdorff; Anthony Maraveyas; Majbrit V Holm; Giovanni Pisa
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 9.  Cancer-Associated Thrombosis: A New Light on an Old Story.

Authors:  Sidrah Shah; Afroditi Karathanasi; Antonios Revythis; Evangelia Ioannidou; Stergios Boussios
Journal:  Diseases       Date:  2021-05-04

10.  Use of antithrombotics at the end of life: an in-depth chart review study.

Authors:  Bregje A A Huisman; Eric C T Geijteman; Jimmy J Arevalo; Marianne K Dees; Lia van Zuylen; Karolina M Szadek; Agnes van der Heide; Monique A H Steegers
Journal:  BMC Palliat Care       Date:  2021-07-16       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.